CytomX Therapeutics
CTMX • NASDAQ
CytomX Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Sean A. McCarthy, with a market cap of $977.1M.
CEOSean A. McCarthy
Next Earnings
Upcoming earnings announcement for CytomX Therapeutics
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.12
Revenue Estimate
$4.2M
Earnings History
Past 12 earnings reports for CytomX Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | Q4 2025 | -$0.22Est: -$0.09 | -144.4% | $663.0KEst: $7.3M | -91.0% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.09Est: -$0.04 | -125.0% | $6.0MEst: $12.0M | -50.4% | 10-Q |
| Aug 7, 2025 | Q2 2025 | $0.00Est: -$0.06 | +100.0% | $18.7MEst: $18.3M | +2.1% | 10-Q |
| May 12, 2025 | Q1 2025 | $0.27Est: $0.13 | +107.7% | $50.9MEst: $35.4M | +43.8% | 10-Q |
| Mar 6, 2025 | Q4 2024 | $0.23Est: -$0.11 | +309.1% | $38.1MEst: $13.0M | +192.1% | 10-K |
| Nov 7, 2024 | Q3 2024 | $0.07Est: -$0.17 | +141.2% | $33.4MEst: $17.5M | +90.9% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.08Est: -$0.14 | +42.9% | $25.1MEst: $20.0M | +25.6% | 10-Q |
| May 8, 2024 | Q1 2024 | $0.17Est: -$0.06 | +383.3% | $41.5MEst: $22.0M | +88.3% | 10-Q |
| Mar 11, 2024 | Q4 2023 | $0.01Est: -$0.03 | +133.3% | $26.6MEst: $21.0M | +26.5% | 10-K |
| Nov 7, 2023 | Q3 2023 | $0.04Est: -$0.19 | +121.1% | $26.4MEst: $14.1M | +86.6% | — |
| Aug 8, 2023 | Q2 2023 | -$0.02Est: -$0.20 | +90.0% | $24.7MEst: $13.9M | +78.1% | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.05Est: -$0.11 | +54.5% | $23.5MEst: $19.6M | +20.0% | — |